Beamion LUNG-1 is an ongoing, first-in-human, open-label study evaluating the safety and efficacy of zongertinib (a selective covalent HER2 TKI) [19] in HER2-mutant NSCLC patients (Stage IB). Here, ERBB2 is linked to non-small cell lung carcinoma.